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High Relapse-Free Survival After
Preoperative and Intraoperative
Radiotherapy and Resection for Sulcus
Superior Tumors*
Albertus N. van Geel, MD, PhD; Peter P. Jansen, MD;
Rob J. van Klaveren, MD, PhD; and Joost R. M. van der Sijp, MD, PhD†;
on behalf of the Rotterdam Oncological Thorax Study Group
Study objectives: Relapse-free survival in patients with sulcus superior tumors.
Design: Prospective registration study.
Setting: Department of surgical oncology of a university hospital.
Patients: Twenty-one patients treated with preoperative radiotherapy (46 Gy), lobectomy and
chest-wall resection, and intraoperative radiotherapy (10 Gy).
Results: After a median follow-up of 18 months, 18 patients (85%) were free from locoregional
relapse, while 8 patients were still alive.
Conclusions: The results show that this protocol can achieve excellent local tumor control and can
even be used for palliative treatment. (CHEST 2003; 124:1841–1846)
Key words: brachytherapy; chest wall resection; external beam radiotherapy; lung cancer; sulcus superior tumor
Abbreviations: FIT  flexible intraoperative template; SST sulcus superior tumor
A sulcus superior tumor (SST) was first publishedas a case report by Hare1 in 1838. In 1924, Henry
Pancoast2 described an unusual growth in the apical
region of the lung, and 8 years later he reported a
syndrome caused by this particular growth in seven
patients; since that time it has been referred to as a
Pancoast tumor. Because other malignant tumors,
such as soft-tissue sarcomas, can cause the same
symptoms, these tumors are currently called SSTs.
SSTs are rare, comprising  5% of all lung cancers.
An SST caused by primary lung cancer occurs in the
apex of the lung and frequently invades the upper
two of three ribs, the vertebral body, the lower part
of the brachial plexus (C8, Th1, and Th2), the
stellate ganglion, and the subclavian vessels.
For the mentioned reasons, the natural course of a
SST typically has a very high morbidity caused by
pain in the C8, Th1, and Th2 dermatomes (invasion
of the brachial plexus), impaired arm and shoulder
function (motor nerve damage), hoarseness (paraly-
sis of the recurrent nerve), Horner syndrome (inva-
sion of the sympathic branches), pulmonary symp-
toms, and weight loss. Almost all patients will die
within 12 months after diagnosis.3 Because SSTs are
in close proximity to vital structures such as the
brachial nerve plexus, brachial vein/artery, and the
vertebral bodies, it was for long thought that the SST
was not amenable to surgery.
Palliative treatment by radiotherapy alone was first
described by Haas et al,4 a relatively long survival has
been reported with this technique.5 Shaw and col-
leagues6 described the combination of surgery and
radiotherapy in 18 patients, 12 of whom were still
alive at (the relatively short) follow-up. Since the
work of Paulson,7 surgery combined with radiother-
apy has become the standard treatment for SST:
patients without lymph node metastases had a 5-year
survival rate of 31%.
Factors associated with a poor prognosis are N2
and N3 disease, T4 disease (invasion of great vessels
or vertebral body), incomplete resections, and Hor-
ner syndrome.8–11 Clinical factors associated with
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improved survival include good performance status,
a weight loss of  5%, and achievement of local
tumor control and pain relief after treatment.12
The optimal combined management of SST re-
mains controversial. Various combinations of surgery
and radiotherapy have been reported. Preoperative
radiotherapy followed by surgical resection with or
without intraoperative or postoperative radiotherapy
resulted in a mean 5-year overall survival rate of
25%, surgery followed by intraoperative or postop-
erative radiotherapy had a mean 5-year survival rate
of 17%, and radiotherapy as a single modality a mean
5-year survival rate of 15%.3,12 Although preopera-
tive radiotherapy followed by surgery appears supe-
rior to radiotherapy alone, this has not been con-
firmed by randomized clinical trials. Even the use of
intraoperative radiotherapy as a goal for optimal
delivery of the radiation dose is under debate8;
however, due to differences in staging, inclusion
criteria, and uneven distribution of prognostic fac-
tors, a meaningful comparison between series is not
possible.12 With the combined treatment it is be-
lieved that the prognosis of SST is comparable to
that of other lung cancers invading the chest wall
(stage IIB).13
Distant metastases (especially brain metastasis)
are the most common cause of relapse (40 to 80%),
particularly in patients with large-cell carcinoma and
adenocarcinoma. After distant relapse, almost all
patients die within 1 year.1,2,12
Data on local tumor control after combined treat-
ment are scarce and conflicting. Even if prognosis is
poor, local tumor control is of importance from a
palliative point of view. The aim of the present study
is to investigate the effect of intraoperative brachy-
therapy in combination with preoperative external
beam radiotherapy and resection on local relapse-
free survival.
Patients and Methods
Between June 1996 and March 2001, 26 consecutive patients
with the clinical diagnosis of SST were entered in a strict protocol
for staging and treatment (Table 1). Of these, 23 patients were
considered resectable with curative intent based on clinical and
radiologic staging and negative mediastinoscopic findings. Radio-
logic staging consisted of a spiral CT-scanning protocol of the
thorax and the thoracic inlet (slice distance 5 mm) and use of an
IV contrast agent. The adrenal glands were also scanned to
exclude adrenal metastases. Cervical mediastinoscopy was per-
formed using a protocol in which at least the lymph nodes
according to Naruke et al14 (No. 2, No. 4, and No. 7) were
sampled. The follow-up period lasted until January 2002 (ranging
from 5 to 58 months).
Preoperative Radiotherapy
The preoperative external beam radiotherapy consisted of 46
Gy in 23 fractions: 2 Gy per fraction, 5 fractions per week. The
treatment was CT planned, and usually two anterior-posterior/
posterior-anterior fields were used. The target volume included
the primary tumor, with at least 2-cm margin, the ipsilateral
supraclavicular fossa, the whole vertebral bodies at the level of
the primary tumor and the ipsilateral mediastinal lymph nodes
(locations 1 to 4). The cranial field border was usually placed
above C6 and the caudal border at the level of the tracheal carina.
In case of N1 nodes, the hilar region was also included. After
radiotherapy, a new CT scan of the chest was made including the
adrenals. If no progression was found, surgery was performed 4
to 6 weeks after the radiotherapy (Fig 1).
Surgery
All patients were operated in the same institution by two
experienced surgeons working in close collaboration with one of
the radiotherapists. The SST was resected by means of a high
extended posterolateral approach. In three patients with an
anterior-mediastinal localization, a hemi-clamshell incision was
carried out.15 The goal was a radical resection (R0) of at least the
upper lobe en bloc with the chest wall. Only in the anterior chest
wall resection, an artificial layer was used for reconstruction. For
the posterior localization, the scapula was considered to be
sufficient as a firm chest wall coverage. Postoperative mortality
was defined as death within 4 weeks after surgery.
Intraoperative Radiotherapy
Instead of using catheters (which have to be fixed separately),
a so-called flexible intraoperative template (FIT) was used to
deliver a homogenous dose to a surface to which the shape of the
mold is adjusted.16 This is a flexible 5-mm-thick silicone mold in
which afterloader catheters are inserted parallel to each other at
a fixed distance of 1 cm (Fig 2). The tumor bed was clipped by
the surgeon, and the FIT was shaped and fixed to the target area.
After inserting dummy catheters, orthogonal x-rays are made of
the implant and loaded into the planning system. The treatment
plan is generated with the indicated active dwell positions of the
catheters. The radiation is delivered during remote-controlled
anesthesia. A single radiation fraction of 10 Gy was administered,
specified in a plane parallel to the surface of the FIT at 1-cm
Table 1—Selection Criteria for Patients Participating
in the Current SST Study
1) World Health Organization pathologic stage  2.
2) The criteria for SST were fulfilled, ie, tumors arising in the
pulmonary apex with invasion of the first, second, or third rib
and pain in dermatomes C8, Th1, or Th2.
3) Cytologically or histologically proven non-small cell lung
carcinoma stage T3N0-1M0 (IIB–IIIA) or T4N0-1M0 (IIIB).
Mixed forms with small cell lung cancer were excluded.
For T4, extensive destruction of the vertebral body was
considered as nonresectable (as seen on MRI).
4) No evidence of metastatic disease as assessed by physical
examination, CT scan of the thorax and upper abdomen (liver
and adrenals), bone scan, investigation of liver and adrenals by
ultrasound, no longer than 4 wk before start of the treatment.
5) Cervical mediastinoscopy was required for mediastinal lymph
node staging within 4 wk of definitive start of treatment.
6) Informed consent was obtained.
7) No CNS involvement.
8) Horner syndrome is no contraindication for surgery.
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distance (1.25 cm from the catheters) with the MicroSelectron
high-dose rate 192Ir afterloader (Nucletron; Veenendaal, the
Netherlands).
Postoperative Radiotherapy
External radiotherapy (12 2 Gy) was administered for those
patients who proved to be unresectable during thoracotomy.
Results
After the external beam radiotherapy course, three
patients dropped out of the protocol because of
progressive disease resulting in an nonresectable
tumor. We planned for the thoracic inlet resection in
combination with intraoperative radiotherapy in 23
patients. Thoracotomy revealed that two patients had
no chest wall invasion; these patients only had
adhesions to the chest wall not requiring a chest wall
resection, and therefore intraoperative radiation was
considered not beneficial and thus not performed.
Finally, 21 patients (12 women and 9 men) under-
went the entire planned treatment schedule, includ-
ing resection and intraoperative radiotherapy. Their
mean age was 58 years (range, 38 to 78 years). The
preoperative clinical staging was stage IIB (all
T3N0M0) in 18 patients, and stage IIIB (all
T4N0M0) in 3 patients.
The pathologic diagnosis of the SST was as follows:
squamous cell carcinoma (n 12), adenocarcinoma
(n  4), and large-cell undifferentiated carcinoma
(n  5). Three patients entered the protocol without
definitive pathologic diagnosis before starting treat-
ment, but the fine-needle aspiration showed malig-
nant cells. In two patients after resection, only
necrosis could be found in the surgical specimen; in
the third patient, residual squamous-cell carcinoma
was present.
Of the 21 patients who underwent a resection,
three ribs were resected in 10 patients, four ribs in 6
patients, and five ribs in 2 patients. In 16 patients, a
lobectomy was performed, 3 patients underwent
bilobectomy, and 4 patients underwent pneumonec-
tomy (Table 2).
Because in most cases, the chest wall defect was
covered by the scapula, in only seven patients (four
patients with a large posterior, and all three patients
with an anterior defect) a reconstruction was madeFigure 2. FIT device.
Figure 1. Staging and treatment algorithm. RT radiotherapy; LN  lymph nodes; IORT  intra-
operative radiotherapy.
www.chestjournal.org CHEST / 124 / 5 / NOVEMBER, 2003 1843
 at Swets Subscription Service on November 7, 2006 www.chestjournal.orgDownloaded from 
using an artificial layer (Composix; Bard/Davol;
Cranston, RI) was used to obtain chest wall stability.
Complication
One patient died 1 week after the operation because
of cardiac failure. The postoperative mortality is 1 of 23
patients (4%). Another patient was readmitted in the
hospital with a bronchopleural fistula and sepsis, and
died 7 weeks after surgery. Two patients had a pro-
longed hospital stay of  3 weeks because of ARDS
and pleural empyema; both recovered after intensive
conservative treatment. In this retrospective analysis,
no detailed information was available about functional
morbidity and the use of analgesics.
Follow-up
In 21 patients, after a median follow-up of 18
months (range, 5 to 58 months), 8 patients were alive
(37%), of which 7 had no evidence of disease
(median follow-up, 24 months; range, 6 to 58
months). Thirteen patients died, all but one with
metastatic disease (63%). The first site of distant
relapse was lung (n  3), bone (n  2), brain
(n  2), soft tissue (n 2), and visceral (n 2). The
median survival after treatment of SST for this group
of patients was 14 months, and the median survival
after distant relapse was 6 months (range, 1 to 15
months). At the end of the study, 18 patients (85%)
were free from locoregional relapse (median
follow-up of 18 months). All five patients who had
a local relapse after 8 to 16 months (median,
11 months) underwent a R1 resection (macroscopic
radical, but at microscopic examination no tumor-
free margins). Two of them had a locoregional
recurrence without distant metastases. The median
survival of all patients with a relapse was 5 months
(range, 1 to 15 months).
Discussion
Earlier reports of treatment of SST have only
historical value because major improvements have
been made in staging (CT scan, MRI, (video-)
mediastinoscopy and, more recently, positron emis-
sion tomography and endoscopic ultrasonography),
surgical skills (type of incision), and radiotherapy
(treatment planning and delivery). Most surgical
series reported in the recent literature show a 5-year
survival rate of 10 to 40%, with a calculated median
of 32  12% ( SD).17 There are indications that
the prognosis of SST can be improved results when
the combination of preoperative and/or postopera-
tive radiotherapy and surgery is used whether or not
Table 2—Characteristics of 21 Patients Treated With Radiotherapy (External Beam and Intraoperative) and
Surgery for SST*
Patient Gender/
Age, yr UICC Stage Pathology Resection
Necrosis,†
%
Local Relapse,
mo
Distal Relapse,
mo
Overall Survival,
mo Status
Female/47 IIB Adeno R1 50 8 8 17 Dod
Female/40 IIB Squam R1 75 4 5 Dod
Male/62 IIIB Squam R2 25 8 8 9 Dod
Female/43 IIB Undiff R0 90 14 Ned
Female/38 IIB Squam R0 0 58 Ned
Female/63 IIB Squam R1 80 6 12 Dod
Female/50 IIB Undiff R2 50 11 13 Dod
Male/67 IIB Squam R0 75 22 Ned
Male/66 IIB Undiff R0 10 8 25 Awd
Female/68 IIB Squam R0 100 11 11 Dod
Female/75 IIB Squam R0 80 4 7 Dod
Male/67 IIB Adeno Adh 0 28 43 Dod
Male/57 IIB Squam R1 50 11 12 Dod
Female/78 IIB Squam R1 50 9 11 Dod
Female/48 IIIB Adeno R0 50 4 17 Dod
Female/54 IIB Squam R0 80 16 Ned
Female/42 IIIB Squam R0 100 4 11 Dod
Male/71 IIB Undiff R0 90 24 Ned
Female/56 IIB Squam R1 0 6 Ned
Male/59 IIB Undiff Adh 50 23 Ned
Male/67 IIB Adeno R1 25 16 11 22 Dod
*UICC  International Union Against Cancer; Adeno adenocarcinoma; Squam  squamous-cell carcinoma; Undiff undifferentiated carci-
noma; R0  microscopic free margin; R1 macroscopic free but not microscopic free margin; R2 macroscopic no free margin; Adh only
adhesiolysis; Dod  death of disease; Ned no evidence of disease; Awd alive with disease.
†Percentage at pathologic examination of the resected specimen.
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with concomitant chemotherapy.10,11,18 In this series
of SST, a protocol has been used combining optimal
radiotherapy including intraoperative brachytherapy
and resection of the apex of the thoracic wall. In
delivering external beam radiotherapy, concerns
about the tolerance level of the plexus and spinal
cord has to be taken into account. To avoid late
radiation damage of these structures, it is often
impossible to administer a curative dose of radiother-
apy only with external fields. Brachytherapy is by
nature the most conformational technique of radio-
therapy. Boosting the surgical bed, the area with the
highest risk of microscopic residual disease gives a
high extra dose to a thin layer of tissue, while due to
the rapid fall-off of dose, the spinal cord is relatively
spared. Therefore, brachytherapy by means of intra-
operative high-dose rate afterloading irradiation is an
option after approaching the tolerance level (50 Gy)
of the spinal cord by external irradiation, a facility
available in our institute; however, others8 could not
find any advantage for the use of this technique.
In experienced hands, the complex surgical pro-
cedure is feasible without increased morbidity, com-
pared with a lung resection without removing a part
of the chest wall even when preoperative radiother-
apy has been administered. Only our patient who
died after a bronchopleural fistula may be consid-
ered as a complication related to the radiotherapy;
however, published data on additional complications
of radiotherapy are scarce. The complication rate of
1 of 22 patients (4%) is similar to that reported in the
literature of extended lung surgery. Operative mor-
tality is only mentioned in 7 of the 13 reviewed
articles with a median mortality of 3.5 2.9%.17 We
are now prospectively monitoring functional morbid-
ity and use of analgesics, as these subjects are
important parameters related to quality of life. Al-
though the goal of cancer treatment should be tumor
control and improvement of survival, optimal locore-
gional treatment will reflect in better local relapse-
free survival. Because the presence of distant metas-
tases reflects the biological behavior of the primary
tumor, a reduction of local failure rates does not
guarantee a better overall survival rate. In that
respect, SST is no exception. The high morbidity of
local tumor progression and local treatment failure
(pain, nerve damage) does justify aggressive local
treatment,9,11 and the main target should be local
recurrence-free survival, even for those patients with
a rather poor prognosis. Palliative radiotherapy alone
can give local control of  50%. Only a few arti-
cles9,11,14,19 give information on the local control rate
after combined radiation and surgical treatment for
SST; their figures range from 40 to 86%, but neither
this information nor the duration of follow-up is
always clearly stated. Another point of criticism is
that these groups are not homogenous; in some
series, N2 status is included,7,10,11,14 and in others
also concomitant chemotherapy.8,14 In addition,
some patients with probably negative prognostic
factors, such as bad performance status, were also
treated.9,14 In our series of 23 patients with good
performance status, negative mediastinoscopic find-
ings, no concurrent chemotherapy, high-dose radio-
therapy, and resection resulted in a local control rate
of 85%. Excluding the two patients with treatment-
related mortality, the local control rate is 76%. These
figures could probably be further improved with
more aggressive surgery, such as vascular or spine
resection and reconstruction.20–22 In our series, the
number of patients is too small to study the positive
influence of radiotherapy on resection margins and
tumor necrosis, which could be the case.18 In all our
resected specimens necrosis was present, but the
original pathology could not be studied because the
diagnosis was made by brush or percutaneous fine-
needle aspiration. As shown in the present study and
confirmed by others,8–12 the overall survival of pa-
tients with SST remains poor because of the high
distant relapse rate. Induction chemotherapy for
stage IIIA and IIIB lung cancer seems to improve
the survival figures.23 The ongoing study for SST
(Eastern Cooperative Oncology Group S9416, phase
II, including the combination of cisplatin and etopo-
side and radiotherapy [45 Gy] before surgery) ad-
dresses this issue. But whether the chemoradiation
regime will improve resectability figures is question-
able.24 Proper preoperative staging is the corner-
stone in any patient who is candidate for oncologic
surgery. All patients in the present study underwent
CT scanning of the whole thorax and the abdomen.
The primary tumor was investigated to establish its
relationship to the adjacent structures and to exclude
ingrowths in the nerve plexus. CT scanning provided
anatomic information concerning operability, and
the use of IV contrast allowed evaluating compres-
sion or ingrowths in the vascular structures. This is
important for staging procedures in order to exclude
adrenal metastases and pulmonary metastases.25
Whether MRI is superior to CT scanning for preop-
erative planning cannot be concluded from our
study; in case there is doubt about resectability, we
always perform MRI. In a study26 conducted in 1989,
MRI proved superior to CT scanning; because in
that study, all R1 resected patients relapsed, it may
be important to perform MRI in all cases. However,
in the last decades enormous improvements have
been made in both modalities and a comparison
between multislice CT scanning and MRI has not yet
been made.
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Conclusion
Combined radiotherapy and surgery should always
be considered in patients with SSTs. In experienced
centers, this treatment does not result in an in-
creased complication rate. In the present study, use
of intraoperative radiotherapy resulted in a local
relapse-free survival of at least 76%, which probably
led to an improvement in quality of life, even in
patients with a limited life expectancy. Improvement
of overall survival in SST is currently studied in
ongoing trials with concomitant radiotherapy and
chemotherapy. Also, attention is paid to morbidity,
functionality, and analgesic requirements. Improve-
ment of staging and preoperative planning will also
improve proper patient selection.
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